List of Excipients in Branded Drug AK-POLY-BAC

Generic Drugs Containing AK-POLY-BAC

Company	Ingredient	NDC	Excipient
Akorn	bacitracin zinc and polymyxin b sulfate	17478-238	MINERAL OIL
Akorn	bacitracin zinc and polymyxin b sulfate	17478-238	PETROLATUM
DIRECT RX	ak-poly-bac	61919-989	MINERAL OIL

What are the Most Frequently-Used Excipients in AK-POLY-BAC?

# Of NDCs	Excipient
2	MINERAL OIL
2	PETROLATUM

AK-Poly-Bac Excipient Strategy and Commercial Opportunities

Last updated: September 29, 2026

AK-Poly-Bac is a sterile ophthalmic ointment containing bacitracin zinc and polymyxin B sulfate. Its commercial formulation uses mineral oil and white petrolatum as the vehicle. The main opportunity is not a novel excipient patent position. It is a reliable, preservative-free generic ophthalmic product with improved supply continuity, packaging, usability, and manufacturing controls.

What is AK-Poly-Bac and which excipients does it contain?

AK-Poly-Bac is an ophthalmic antibacterial ointment marketed by Akorn Operating Company LLC. Each gram contains:

Component	Function	Label concentration
Bacitracin zinc	Antibacterial active	500 units/g
Polymyxin B sulfate	Antibacterial active	10,000 units/g
Mineral oil	Ointment vehicle and emollient	Quantity sufficient
White petrolatum	Primary ointment base and occlusive vehicle	Quantity sufficient

The product is indicated for superficial ocular infections caused by susceptible bacteria. The label identifies mineral oil and white petrolatum as inactive ingredients and does not identify a preservative, aqueous buffer, surfactant, or penetration enhancer (DailyMed, n.d.-a).

The formulation is technically conventional but commercially practical. A hydrophobic petrolatum-mineral oil base supports sterility, prolongs ocular residence time, and avoids the preservative exposure associated with multidose aqueous eye drops.

What formulation strategy does AK-Poly-Bac use?

Why are mineral oil and white petrolatum used?

White petrolatum provides the structural matrix for the ointment. Mineral oil adjusts consistency, spreadability, extrusion behavior, and the release of suspended or dispersed active ingredients.

The combination supports several product requirements:

• Ocular residence longer than a conventional aqueous drop
• Low water activity
• Compatibility with a preservative-free presentation
• Protection of the formulation from aqueous hydrolysis pathways
• Low-cost, scalable manufacturing
• Familiarity with ophthalmic ointment compendial practice

The commercial tradeoff is sensory. Ointments can cause temporary blurred vision, greasiness, and patient inconvenience. Those attributes create an opening for alternative dosage forms, but they also make the established ointment format attractive for nighttime dosing and short-duration treatment.

What critical quality attributes should manufacturers control?

Quality attribute	Commercial relevance
Sterility	Mandatory for ophthalmic administration
Uniform active distribution	Prevents dose variability across the tube
Ointment consistency	Controls tube extrusion and ocular application
Particle size and agglomeration	Affects irritation, uniformity, and release
Assay and potency	Particularly important for antibiotic activity units
Water content	Influences stability and microbial risk
Tube fill weight	Affects labeled supply and patient use
Container-closure integrity	Protects sterility throughout shelf life
In-use performance	Determines contamination risk after opening

Bacitracin zinc and polymyxin B sulfate are microbiologically active substances rather than conventional small-molecule ingredients with simple mass-based potency alone. Release specifications therefore require chemical and microbiological controls appropriate to each active ingredient.

What excipient changes could create commercial opportunities?

The strongest opportunities are incremental formulation improvements that preserve the established ophthalmic ointment profile.

Lower-viscosity ophthalmic ointment

A lower-viscosity vehicle could improve administration and reduce the sensation of a heavy ocular film. The formulation must remain sufficiently cohesive to prevent leakage and maintain ocular residence.

Potential development variables include:

• Mineral oil-to-petrolatum ratio
• Petrolatum grade and consistency
• Hydrocarbon distribution
• Mixing temperature and shear
• Active powder wetting and dispersion
• Tube or nozzle geometry

A viscosity reduction that causes phase separation, sedimentation, or poor dose uniformity would create regulatory and product-quality risk.

Improved active dispersion

Uniform dispersion is a major technical issue for a dual-antibiotic ointment. Particle-size control, deagglomeration, and mixing sequence can improve:

• Content uniformity
• Microbiological potency consistency
• Ocular tolerability
• Batch-to-batch reproducibility
• Stability during storage

A process patent may be more defensible than a simple excipient substitution if it links the manufacturing method to measurable improvements in uniformity, potency, or stability.

Reduced grittiness and ocular irritation

The product may be improved through tighter control of active particle size and the use of ophthalmic-grade excipients with controlled impurity profiles. A manufacturer should avoid relying on generic cosmetic-grade petrolatum or mineral oil. Ophthalmic excipient qualification requires attention to hydrocarbons, peroxides, metals, sulfur compounds, and particulate contamination.

Potential claims could cover:

• Defined particle-size distribution
• Specific active-to-vehicle ratios
• Reduced visible or subvisible particulate matter
• Improved ocular comfort
• Controlled extrusion force
• Reduced active agglomeration

Unit-dose packaging

Unit-dose tubes or sterile single-use sachets could reduce contamination risk and improve suitability for hospitals, surgery centers, and post-procedure use. The disadvantages are higher packaging cost, greater material consumption, and potential fill-volume inefficiency.

A unit-dose format may be commercially attractive where preservative-free use and contamination control carry greater value than low-cost multidose packaging.

Alternative semi-solid delivery systems

A developer could evaluate:

• Polyethylene glycol-based ophthalmic ointments
• Water-in-oil systems
• Anhydrous organogel systems
• Lipid suspensions
• Thermoresponsive gels
• Low-water-content creams designed for ophthalmic use

These options would create more meaningful formulation differentiation but also introduce larger regulatory and manufacturing burdens. Changes in vehicle composition can alter release, residence time, irritation, sterility assurance, and bioequivalence.

What is the FDA regulatory status of AK-Poly-Bac?

AK-Poly-Bac is an FDA prescription ophthalmic product. Its active ingredients are bacitracin zinc and polymyxin B sulfate, administered as a sterile ophthalmic ointment.

Regulatory element	Assessment
Dosage form	Sterile ophthalmic ointment
Route	Ophthalmic
Prescription status	Prescription
Active ingredients	Bacitracin zinc and polymyxin B sulfate
Preservative	Not identified in the listed inactive ingredients
Regulatory pathway for a copy	Abbreviated New Drug Application, subject to applicable FDA requirements
Primary reference source	FDA labeling and DailyMed product information
Orange Book relevance	Product-specific listing and therapeutic-equivalence status must be verified against the current FDA Orange Book

The commercial formulation should be designed around the reference product's qualitative and quantitative inactive-ingredient profile unless a different composition is supported by FDA requirements and comparative product data. Ophthalmic products face strict expectations for sterility, particulate control, container closure, and product performance.

When does AK-Poly-Bac lose exclusivity?

AK-Poly-Bac does not appear to depend on a major active-ingredient patent or a biologic exclusivity period. Bacitracin and polymyxin B are established antibacterial substances, and the conventional petrolatum-mineral oil vehicle is not itself a strong exclusivity platform.

The practical exclusivity position is therefore driven by:

• FDA approval status
• Product availability
• Manufacturing reliability
• Any current product-specific patents
• Any active regulatory exclusivity
• Market withdrawal or supply constraints affecting competitors
• The cost and complexity of sterile ophthalmic manufacturing

A current Orange Book review is required to establish whether any patents are listed for a specific AK-Poly-Bac application. Public product labeling alone does not establish an exhaustive patent position. No widely recognized composition-of-matter patent protects the active combination.

What patent estate protects AK-Poly-Bac?

The patent estate is likely weak if assessed only on the core formulation of bacitracin zinc, polymyxin B sulfate, mineral oil, and white petrolatum.

Patentability by subject matter

Subject matter	Likely patent strength
Bacitracin plus polymyxin B combination	Low because of long-established use
Petrolatum-mineral oil vehicle	Low because of conventional excipient use
Preservative-free ointment	Low to moderate, depending on specific claims
Controlled particle-size distribution	Moderate if tied to measurable performance
Improved release or residence time	Moderate if supported by comparative data
Unit-dose container system	Moderate, but vulnerable to design-around
Manufacturing process	Moderate where process controls produce unexpected results
Stability improvement	Moderate if supported by robust comparative data
New therapeutic indication	Potentially stronger as a method-of-use claim
New delivery platform	Potentially stronger but commercially riskier

A defensible formulation patent would need more than a list of familiar ingredients. Useful claim scope could include narrow excipient ratios, active particle-size limits, defined rheology, sterility-preserving packaging, or demonstrated improvements in potency retention and ocular tolerability.

Are there Paragraph IV challenges or patent litigation risks?

No prominent Paragraph IV litigation or settlement involving AK-Poly-Bac is established by the product information cited here. Because the product uses old active ingredients and a conventional ointment base, generic competition would more likely involve ANDA approval, manufacturing economics, and product availability than a high-value patent dispute.

A challenger would typically assess:

1. Whether any patents are listed in the Orange Book.
2. Whether the listed patents cover the composition, method of use, or container.
3. Whether a proposed formulation can avoid those claims.
4. Whether the applicant can demonstrate pharmaceutical equivalence and bioequivalence or applicable ophthalmic performance.
5. Whether the reference product remains commercially available for comparison and procurement.

The principal litigation exposure for a new entrant may instead arise from formulation, process, trade-secret, trademark, or contractual disputes.

What generic entry risks exist for AK-Poly-Bac?

Low technical barrier, high quality-system barrier

The active ingredients and excipients are inexpensive. The more significant barriers are:

• Sterile ointment manufacturing capacity
• Qualified ophthalmic filling lines
• Active-ingredient potency control
• Content uniformity
• Tube and nozzle compatibility
• Stability data
• Container-closure integrity
• FDA inspection readiness
• Reliable supply of pharmaceutical-grade petrolatum and mineral oil

A competitor can potentially duplicate the formulation concept. It cannot easily duplicate validated sterile manufacturing performance without investment in equipment, quality systems, testing, and regulatory infrastructure.

Generic launch scenarios

Scenario	Likely commercial effect
One additional approved generic	Price pressure and pharmacy substitution
Multiple approved generics	Rapid margin compression
Reference-product shortage	Temporary premium for available supply
Hospital contracting	Greater emphasis on reliability and unit-dose packaging
Reformulated product with superior usability	Potential niche differentiation
Manufacturing disruption	Short-term market-share gains for alternate suppliers

How does AK-Poly-Bac compare with competing ophthalmic antibiotics?

Product type	Typical vehicle	Main advantage	Main limitation
Bacitracin/polymyxin B ointment	Petrolatum and mineral oil	Long ocular residence and preservative-free profile	Blurred vision and greasy feel
Polymyxin B/trimethoprim solution	Aqueous	Easy daytime administration	Usually requires repeated dosing
Erythromycin ophthalmic ointment	Petrolatum-based	Established ointment format	Different antimicrobial coverage
Fluoroquinolone ophthalmic solution	Aqueous	Broad bacterial coverage and convenient dosing	Preservative and resistance considerations
Aminoglycoside ophthalmic products	Aqueous or ointment	Alternative antibacterial activity	Tolerability and spectrum limitations

AK-Poly-Bac is most defensible in segments that value ointment residence time and a preservative-free format. It is less differentiated where patients or prescribers prioritize clear vision, rapid administration, and daytime convenience.

What licensing and partnership opportunities exist?

The most realistic commercial partnerships are operational rather than discovery-based.

Contract manufacturing

A specialized ophthalmic contract manufacturer could provide:

• Sterile compounding and filling
• Tube or unit-dose packaging
• Analytical method transfer
• Stability program execution
• FDA quality-system support
• Capacity redundancy

This model is attractive because the formulation is established but sterile ophthalmic capacity is limited.

Private-label and institutional supply

Potential customers include:

• Hospital systems
• Group purchasing organizations
• Ambulatory surgery centers
• Ophthalmology distributors
• Retail pharmacy suppliers
• International generic companies

Private-label supply can generate volume without requiring a large consumer brand investment.

Geographic licensing

The product may have opportunities in markets where ophthalmic antibiotic ointments remain common and local sterile manufacturing is constrained. Geographic expansion requires separate assessment of:

• Local registration requirements
• Accepted pharmacopoeial standards
• Antibiotic naming and potency conventions
• Import controls
• Local patent status
• Pharmacovigilance obligations
• Reimbursement and tender pricing

The United States should not be treated as the only relevant market. The commercial case may be stronger in countries with hospital procurement shortages or limited local ophthalmic manufacturing.

How strong is the commercial patent strategy?

The current core composition is a weak platform for broad exclusivity. A stronger strategy would combine:

1. A formulation patent covering a defined vehicle and particle-size profile.
2. A process patent covering dispersion, sterilization, filling, or stability control.
3. A packaging patent covering unit-dose delivery or contamination reduction.
4. Regulatory differentiation based on reliable supply, preservative-free positioning, or institutional use.
5. Trademark and supply agreements to protect commercial channels.

Patent value would depend on comparative data. Claims supported only by routine optimization are vulnerable to obviousness attacks and design-around strategies.

Key Takeaways

• AK-Poly-Bac contains bacitracin zinc and polymyxin B sulfate in a mineral oil and white petrolatum ophthalmic ointment.
• The excipient system is conventional, low cost, and compatible with a preservative-free sterile product.
• The best formulation opportunities are improved active dispersion, lower viscosity, reduced grittiness, unit-dose packaging, and better extrusion performance.
• The core formulation is unlikely to support broad, durable patent exclusivity without narrow technical limitations and comparative data.
• Commercial barriers are concentrated in sterile manufacturing, quality control, container closure, and supply reliability.
• Generic competition is more likely to be driven by FDA approval and manufacturing economics than by major Paragraph IV litigation.
• Contract manufacturing, hospital supply, private-label distribution, and geographic licensing are the strongest commercial pathways.
• Product-level revenue exposure cannot be reliably inferred from the public label because standalone AK-Poly-Bac sales are not separately disclosed.

FAQs

Is AK-Poly-Bac preservative-free?

The listed inactive ingredients are mineral oil and white petrolatum, and the labeling does not identify a conventional preservative. The product is presented as a sterile ophthalmic ointment.

Can mineral oil and white petrolatum be replaced in an AK-Poly-Bac generic?

They can potentially be replaced, but a changed vehicle may affect pharmaceutical equivalence, release, residence time, sterility, irritation, and regulatory comparability. A generic developer would need to support the alternative formulation with appropriate FDA data.

Does AK-Poly-Bac have a biosimilar risk?

No. AK-Poly-Bac is a conventional sterile ophthalmic drug product, not a biologic. Its competitive risk comes from generic ophthalmic products, not biosimilars.

What is the most valuable excipient innovation for this product?

A formulation that improves ocular comfort and extrusion while preserving sterility, active uniformity, potency, and residence time has the clearest commercial value. Unit-dose packaging is the strongest adjacent delivery opportunity.

Could a new AK-Poly-Bac formulation obtain a method-of-use patent?

Potentially, but a method-of-use claim would need a novel, legally protectable use supported by clinical or regulatory evidence. A routine claim for treating the same established superficial ocular infections would face substantial validity risk.

References

1. DailyMed. (n.d.-a). AK-Poly-Bac ophthalmic ointment: Bacitracin zinc and polymyxin B sulfate prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book

3. U.S. Food and Drug Administration. (n.d.-b). Sterile drug products produced by aseptic processing: Current good manufacturing practice. FDA. https://www.fda.gov/

4. United States Pharmacopeia. (2024). General chapter <771>: Ophthalmic products. United States Pharmacopeial Convention.

5. United States Pharmacopeia. (2024). General chapter <797>: Pharmaceutical compounding: Sterile preparations. United States Pharmacopeial Convention.